Company Intelligence
Zai Lab
再鼎医药
No Known BCC Exposure
Zai Lab is a drug innovator and commercializer, not a CDMO/CRO. Dual-listed on NASDAQ with US headquarters in Cambridge, MA. No BIOSECURE exposure.
Overview
Zai Lab (再鼎医药) operates a unique bi-directional licensing model: it licenses Western and Chinese innovative drugs for the Greater China market while developing its own pipeline for global out-licensing. The company has established a strong commercial infrastructure in China and is one of the few Chinese biotechs with a fully integrated discover-develop-commercialize capability across both markets.
Key Facts
- Bi-directional licensing model: imports Western drugs into China and exports Chinese innovation globally
- Commercial operations in Greater China with established sales force
- NASDAQ and HKEX dual-listed — one of the most transparent Chinese biotechs for Western investors
- Key partnerships include licenses from GSK, MacroGenics, and Turning Point Therapeutics (now Bristol-Myers Squibb)
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Various (in-licensing) | Ongoing | Multiple | GSK, MacroGenics, and other Western assets for Greater China |
Corporate Structure
Cayman Islands holding company. Dual-listed on NASDAQ and HKEX. US operations through Zai Lab US LLC (Cambridge, MA). China operations through Zai Lab (Shanghai) Co., Ltd. Founded by Dr. Samantha Du (杜莹), former VP at Pfizer.